A Combined Therapy with Myo-Inositol and D-Chiro-Inositol Improves Endocrine Parameters and Insulin Resistance in PCOS Young Overweight Women
Elena Benelli, Scilla Del Ghianda, Caterina Di Cosmo, and Massimo Tonacchera
Department of Clinical and Experimental Medicine, Section of Endocrinology, University Hospital of Pisa,
Via Paradisa 2, 56124 Pisa, Italy
Correspondence should be addressed to Massimo Tonacchera; firstname.lastname@example.org
Received 13 April 2016; Accepted 24 May 2016
Academic Editor: Vittorio Unfer
Copyright © 2016 Elena Benelli et al.This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Introduction. We evaluated the effects of a therapy that combinesmyo-inositol (MI) andD-chiro-inositol (DCI) in young overweight women affected by polycystic ovary syndrome (PCOS), characterized by oligo- or anovulation and hyperandrogenism, correlated to insulin resistance. Methods. We enrolled 46 patients affected by PCOS and, randomly, we assigned them to two groups, A and B, treated, respectively, with the association of MI plus DCI, in a 40 : 1 ratio, or with placebo (folic acid) for six months. Thus, we analyzed pretreatment and posttreatment FSH, LH, 17-beta-Estradiol, Sex Hormone Binding Globulin, androstenedione, free testosterone, dehydroepiandrosterone sulphate, HOMA index, and fasting glucose and insulin. Results.We recorded a statistically significant reduction of LH, free testosterone, fasting insulin, andHOMAindex only in the group treatedwith the combined therapy of MI plus DCI; in the same patients, we observed a statistically significant increase of 17-beta-Estradiol levels. Conclusions. The combined therapy of MI plus DCI is effective in improving endocrine and metabolic parameters in young obese PCOS affected wome.